Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

CONCLUSION: Anlotinib demonstrates its efficacy and safety in this phase ⅡB trial for the treatment of MTC and may become a new choice for this rare disease, especially for Chinese patients.PMID:33832949 | DOI:10.1158/1078-0432.CCR-20-2950
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research